Johnson Philip L 4

What Happened

• Philip L. Johnson, Chief Financial Officer of Jazz Pharmaceuticals (JAZZ), received a grant of 11,857 restricted stock units (RSUs) on February 26, 2026. The units were reported as acquired at $0.00 (a compensation award rather than an open-market purchase).
• Each RSU represents a contingent right to one ordinary share upon vesting; the award’s vesting schedule begins March 5, 2026 and vests in equal annual installments over four years (1/4 on the first anniversary, then annually thereafter).

Key Details

• Transaction date: February 26, 2026; filing date: March 2, 2026 (filed within the SEC’s two-business-day window).
• Reported acquisition: 11,857 RSUs at $0.00 (code A — award/grant).
• Vesting commencement date: March 5, 2026; vesting: equal annual installments over four years.
• Filing notes prior small share purchases by the reporting person: 166 ordinary shares on May 30, 2025 and 140 shares on November 28, 2025 under the company’s Section 423 Employee Stock Purchase Plan (per footnote).
• The filing does not specify the total number of shares owned by the reporting person after this grant.

Context

• RSU grants are common executive compensation and do not represent immediately tradable shares until they vest; they are contingent on service and/or other conditions described in the plan.
• This transaction is an award (compensation) rather than a purchase or sale, so it should be viewed as routine executive compensation disclosure, not a direct buy/sell signal.